Blood Preparation Market

Market Overview The global blood preparation market is projected to expand significantly, rising from USD 44.14 billion in 2025 to USD 64.37 billion by 2031, demonstrating a compound annual growth rate of 6.49%. This market involves the methodical collection, screening, and fractionation of whole blood into vital therapeutic components like red blood cells, platelets, and plasma for various medical uses. Key factors driving this growth include the increasing incidence of chronic hematological disorders and a heightened need for blood transfusions during intricate surgical procedures and trauma incidents. Moreover, the growing elderly population presents a unique growth driver, as this demographic frequently requires prolonged blood-based treatments for disease management, which consistently fuels the demand for blood preparation technologies and associated consumables. However, the market faces a substantial hurdle concerning the stability of its supply chain and persistent inventory shortages, which hinder the timely availability of essential products. This issue is compounded by fluctuating donor retention rates and logistical difficulties in maintaining adequate stockpiles; for instance, according to the Association for the Advancement of Blood & Biotherapies, obtaining O-negative and B-negative blood in December 2025 often took forty-eight hours or more due to supply limitations. Such delays underscore an operational vulnerability that could impede broader market expansion. Market Driver The blood preparation sector is significantly propelled by the increasing adoption of novel oral anticoagulants (NOACs) and advanced therapeutic options, particularly those derived from plasma. As healthcare providers increasingly opt for targeted treatments for conditions like immune deficiencies and autoimmune neuropathies, there is a heightened requirement for precise fractionation and component separation technologies to guarantee product purity and effectiveness. This surge in demand is evident in the strong financial performance of leading industry players who are scaling operations to meet global therapeutic needs; for example, Grifols reported a robust 15.3% full-year growth in its immunoglobulin franchise in February 2025, driven by strong global underlying demand. Concurrently, the rising volume of emergency trauma cases and the evolution of prehospital care protocols are accelerating market momentum. Healthcare systems are increasingly integrating whole blood and specific component therapies directly into emergency response vehicles to improve survival rates for trauma victims experiencing severe hemorrhage. This strategic shift necessitates the expansion of localized processing capabilities and specialized storage solutions beyond traditional hospital environments. According to America's Blood Centers, the number of community blood centers providing blood products for specialized prehospital programs nearly doubled to 34 between 2022 and 2024. This operational expansion helps balance the ongoing pressures of chronic disease management, as projected new cancer cases in the United States, estimated at 2,041,910 in 2025 by the American Cancer Society, maintain a consistently high baseline demand for transfusions alongside emergency utilization. Market Challenge The blood preparation market operates in a volatile environment characterized by supply chain instability and persistent inventory shortages. When blood collection centers cannot maintain adequate stock levels, the utilization of preparation technologies and consumables inevitably declines due to insufficient raw material for processing. This operational bottleneck significantly restricts the ability of market participants to scale their processing capabilities and efficiently fulfill hospital orders. Furthermore, the unpredictable nature of donor turnout leads to operational inefficiencies, forcing facilities to operate below their full capacity while still incurring fixed costs for equipment maintenance and labor. These recurring shortages directly reduce the volume of blood products available for therapeutic applications, thereby stalling revenue recognition for processing entities. The inability to secure a consistent inflow of whole blood means that demand from healthcare providers often remains unmet, causing disruptions throughout the market ecosystem. For instance, the American Red Cross reported a national blood supply drop of over 25 percent in a single month during August 2024, creating a critical inventory gap. Such significant deficits impede the consistent application of essential screening and fractionation processes, ultimately limiting the overall market growth potential during periods of scarcity. Market Trends The integration of Pathogen Reduction and Inactivation Technologies is fundamentally reshaping market dynamics by prioritizing transfusion safety and extending the longevity of blood inventories. Blood centers are rapidly deploying advanced systems that employ photochemical processes to neutralize pathogens in platelets and plasma, thereby effectively minimizing the risk of bacterial contamination and transfusion-transmitted infections without solely relying on detection methods. This technological shift not only enhances patient safety profiles but also significantly extends the viable shelf life of components, directly addressing critical wastage challenges within the supply chain. For example, Cerus Corporation reported a 15% year-over-year increase in product revenue in November 2025, a surge largely attributed to the robust global demand for its pathogen-reduced platelet and fibrinogen systems. Another significant trend is the Adoption of Automated Blood Component Separation Systems, which are optimizing processing workflows to meet the escalating requirement for high-yield therapeutic products. Facilities are increasingly transitioning from manual separation methods to sophisticated closed-loop automated platforms that efficiently fractionate whole blood or collect specific components via apheresis, consequently improving operational throughput and product consistency. This transition supports scalable production while simultaneously reducing labor dependencies and processing errors, enabling centers to maximize the utility of every donation. Haemonetics Corporation's Plasma segment, for instance, achieved an organic revenue growth of 19% (excluding transitional supply agreements) in its Q2 Fiscal 2026 results in November 2025, reflecting the accelerated industry uptake of next-generation automated collection and separation devices. Key Market Players * Pfizer, Inc. * Bristol-Myers Squibb Company * Leo Pharma A/S * Sanofi S.A. * Xiamen Hisunny Chemical Co., LTD * AstraZeneca plc * Baxter International Inc * Portola Pharmaceuticals, Inc. * GlaxoSmithKline PLC * Shandong East Chemical Industry Co. Report Scope In this report, the Global Blood Preparation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: # Blood Preparation Market, By Product * Whole Blood * Blood Components * Blood Derivatives # Blood Preparation Market, By Type * Platelet Aggregation Inhibitors * Fibrinolytics * Anticoagulants # Blood Preparation Market, By Application * Thrombocytosis * Pulmonary Embolism * Renal Impairment * Angina Blood Vessel Complications * Others # Blood Preparation Market, By Region * North America United States Canada Mexico * Europe France United Kingdom Italy Germany Spain * Asia Pacific China India Japan Australia South Korea * South America Brazil Argentina Colombia * Middle East & Africa South Africa Saudi Arabia UAE Competitive Landscape Company Profiles: Detailed analysis of the major companies present in the Global Blood Preparation Market. Available Customizations: Global Blood Preparation Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: Company Information * Detailed analysis and profiling of additional market players (up to five).